Several other equities research analysts also recently commented on AKBA. ValuEngine raised shares of Akebia Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Akebia Therapeutics from a sell rating to a hold rating in a report on Monday, October 21st. HC Wainwright reduced their price target on shares of Akebia Therapeutics from $17.00 to $16.00 and set a buy rating for the company in a report on Monday. Needham & Company LLC reduced their price target on shares of Akebia Therapeutics from $18.00 to $15.00 and set a buy rating for the company in a report on Thursday, November 14th. Finally, Mizuho reiterated a buy rating and issued a $16.00 price target on shares of Akebia Therapeutics in a report on Tuesday. One analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $12.71.
NASDAQ:AKBA traded up $0.75 during trading hours on Thursday, hitting $4.21. The stock had a trading volume of 4,042,629 shares, compared to its average volume of 1,069,424. Akebia Therapeutics has a one year low of $2.99 and a one year high of $10.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.82 and a current ratio of 1.34. The company has a market cap of $378.24 million, a price-to-earnings ratio of -1.73 and a beta of 1.51. The business’s 50 day moving average is $3.91 and its 200-day moving average is $4.39.
In related news, CEO John P. Butler purchased 50,000 shares of Akebia Therapeutics stock in a transaction dated Wednesday, November 20th. The stock was bought at an average price of $3.44 per share, for a total transaction of $172,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 63,700 shares of the company’s stock, valued at $219,128. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Steven Keith Burke purchased 27,000 shares of Akebia Therapeutics stock in a transaction dated Wednesday, November 20th. The stock was bought at an average price of $3.58 per share, with a total value of $96,660.00. Following the acquisition, the senior vice president now directly owns 37,000 shares of the company’s stock, valued at $132,460. The disclosure for this purchase can be found here. Insiders bought 82,800 shares of company stock valued at $288,554 in the last quarter. Corporate insiders own 2.66% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Strs Ohio boosted its holdings in shares of Akebia Therapeutics by 6.0% in the second quarter. Strs Ohio now owns 47,800 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 2,700 shares during the period. M&T Bank Corp boosted its holdings in Akebia Therapeutics by 24.9% during the second quarter. M&T Bank Corp now owns 14,507 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 2,894 shares during the last quarter. Sun Life Financial INC boosted its holdings in Akebia Therapeutics by 9.3% during the second quarter. Sun Life Financial INC now owns 34,162 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 2,907 shares during the last quarter. Aperio Group LLC acquired a new position in Akebia Therapeutics during the second quarter worth $31,000. Finally, Tower Research Capital LLC TRC acquired a new position in Akebia Therapeutics during the third quarter worth $30,000. Institutional investors own 72.59% of the company’s stock.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
See Also: Is the QQQ ETF safe?
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.